Eli Lilly defeat shows one size does not fit all in obviousness test: lawyers
28-03-2019
Eli Lilly defeated as Cialis patent found obvious on appeal
01-11-2017
Eli Lilly settles Cialis patent litigation with generic makers
18-07-2017
Jonathan Weiss / Shutterstock.com
The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Eli Lilly, Cialis, erectile dysfunction, Teva, Mylan, Actavis, patent validity, UK Supreme Court, Cilias, tadalafil
